A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

Inclusion Criteria: Male or female, 1 to 24 months (inclusive) at screening; Weight: 3-20 kg, inclusive; Positive RSV test within 36 hours before randomization; Symptomatic at screening and randomization, and the onset of RSV symptoms is within 5 days prior to the first dose of XW001; Parents/legal guardians are able to understand the purpose and procedures of the study, and are able to provide informed consent. Exclusion Criteria: Immunocompromised as determined by the investigator; Known to have undergone or planned for bone marrow, stem cells, or other organ transplants, or are currently on immunosuppressive treatment; Positive for HBV, HCV or HIV, or patient <6 months old whose mother is positive for HIV; History of seizures or epilepsy, including febrile seizure; Known to have received any prohibited medications defined by the protocol within 3 days prior to randomization; History of any surgery within 30 days prior to randomization; Severe dental or facial deformity that will impact on usage of nebulizer; History of receiving measles, mumps, rubella or other vaccines within 7 days prior to screening; Known to have received any investigational medicinal products or devices in the past 30 days; Any other underlying conditions that make the patient unlikely to complete the study in the opinion of the investigator.